Champions Biotechnology, Inc. Retains The Investor Relations Group

Arlington, VA – August 14, 2008 – Champions Biotechnology, Inc. (OTCBB: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has retained the Investor Relations Group (IRG) to serve as its first investor relations and public relations firm in order to achieve greater recognition in the financial and media communities.

“Given the business progress we’ve made, it’s important for the Company to gain increased visibility,” said Douglas Burkett, PhD, President of Champions Biotechnology, Inc. We look forward to embarking upon our relationship with IRG, one that will focus on building awareness and communicating our technology advantages and business objectives to the investment community and the media-at-large.”

“We believe that our Biomerk Tumorgrafts™ accurately predict the outcome of Phase II clinical trials,” said Dr. Manuel Hidalgo, Champions Biotechnology’s Chief Scientist. “The ability to test and predict which early stage drug candidates have the best chance to succeed in human clinical trials is of profound value and benefit to pharmaceutical and biotech companies, as well as to our own drug development program as we seek drug partnerships and acquisitions to expand our oncology drug pipeline. It is our goal to leverage the unique value of Biomerk Tumorgrafts to generate future revenues through royalty arrangements, partnerships, and acquisitions.”

IRG, a highly recognized, New York-based corporate communications firm, will strive to increase Champions Biotechnology’s public exposure, communicate the advantages of its technology, and explain its high potential growth objectives through a focused campaign. On the investor relations front, IRG will use its proprietary database of investors to introduce Champions Biotechnology to targeted members of the investment community through pre-qualified one-on-one introductions, e-mails to professionals that have opted-in to receive communication, interviews, and traditional outreach. In the public relations arena, IRG will strive to educate audiences of editors, writers, and segment producers of local and national trade and consumer print, radio, online, and broadcast media outlets about Champions Biotechnology’s technology and its role in the market.